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When I was in college, I had a roommate who was a little
weird. OK - more than a little weird. One night, at about
2 am, the campus police woke me up to tell me that he was
sitting in the middle of the main street of our college town,
naked, with a blanket over his head. They wanted me to go
and bring him home, so they didn’t have to arrest him. I got
dressed, walked into town, and sure enough, there he was,
sitting naked in the middle of the street with a blanket over
his head. I walked over to him, called his name, and said,
“Warren, why are you sitting naked in the middle of Prospect
Street with a blanket over your head at 2 o’clock in the
morning?” He peered out from under the blanket, looked up
at me, and said, “It seemed like a good idea at the time.”
My guess is that whoever was responsible for the Protein
Structure Initiative (PSI) must have felt the same way. The
PSI is a fancy name for the US ‘Structural Genomics’ effort.
The stated aim of Structural Genomics is determination of
the three-dimensional structures of all proteins. Its members
and proponents claim that this aim can be achieved in four
steps: first, organizing known protein sequences into
families; second, selecting family representatives as targets;
third, solving the three-dimensional structures of targets by
X-ray crystallography or NMR spectroscopy; and fourth,
building models for other proteins by homology to solved
three-dimensional structures.
The Initiative currently funds ten large centers scattered
around the United States (similar efforts exist in Europe and
Japan). They are supported for a five-year period to the tune
of about $300 million total. The PSI website
[http://www.nigms.nih.gov/Initiatives/PSI/] states that
“Expected benefits from the PSI include: structural
descriptions to help researchers discover the functions of
proteins, design experiments, and solve other key bio-
medical problems; faster identification of promising new
structure-based medicines; better therapeutics for treating
both genetic and infectious diseases; and development of
technology and methodology for protein production and
crystallography.” The National Institute of General Medical
Sciences (NIGMS), the main branch of the US National
Institutes of Health (NIH) funding the PSI, is currently
engaged in an assessment of the PSI. I know this because I
was asked to provide my views on the initiative. I’m afraid
they weren’t very complimentary.
The PSI actually has had two incarnations. The specific
goals of PSI-1 (which existed from 2000-2005) were to
develop methodology and technology to increase success
rates and lower costs of structural determination; to
construct and automate the protein production and
structural determination pipeline; and, finally, to
determine unique protein structures. Lots of unique
protein structures. By 2005, it became apparent that most
of these goals weren’t being met, nor were they likely to be
met in the near future.
One of the many great scenes in the wonderful old Errol
Flynn movie ‘The Adventures of Robin Hood’ is the archery
contest. The finest archers from all over the kingdom are
gathered in Nottingham to compete for a gold arrow. After
many rounds, only two competitors are left: Robin Hood,
disguised as a tinker, and one of Sir Guy of Gisborne’s
archers. After they both shoot and both hit the bulls-eye,
Robin Hood asks that the target be moved back, “to a fit
distance for men to shoot at.” When it looked like the PSI
wasn’t going to be able to meet its goals, what did it do? It
moved the target in. The specific goals of PSI-2 (funded from
2005-2010) are now to increase the number of sequence
families with structural representatives, including families
with high biological impact; to continue methodology and
technology development, especially for challenging classes of
proteins such as membrane proteins; and to facilitate the use
of structures by the broad scientific community. These goals
are so squishy, it would almost be impossible not to meet
them. Or for it to matter much if they were.But as I considered my assessment, it became clear to me
that even if the goals of the original PSI-1 could be met, I
wouldn’t care. Nor, I think, should most anyone else.
Do we really need a catalog of structures? What will that
teach us? We already know that proteins are composed of
beta sheets and alpha helices, interspersed with loops.
Filling the fold catalog might be of interest to bioinforma-
ticists, but why should they drive the science that others do?
And I reject categorically the notion that enough structures
will allow us to build homology models for every sequence.
First of all, the methods for recognizing which fold a
sequence belongs to aren’t that robust. False positives seem
to be fairly rare, but false negatives abound. Second,
homology models aren’t very accurate when the sequences
are less than about 50% identical, which happens most of
the time. For drug discovery and understanding bio-
chemistry, accurate models are essential. Nor is it clear to
me that when you have a structure, you necessarily have
learned all that much about the function of the protein. The
coupling between sequence, overall fold, and function is
rather loose. Even when a fold has an accurately annotated
function, which is not as often as it ought to be, there is a
high probability that a homolog with less than about 50%
sequence identity will have a different biochemical and
cellular function. My guess is that a large catalog of
structures will just lead to even more missannotation of
function by homology - one of the greatest problems in
genomics today.
It’s also clear, I think, that it isn’t enough to have the
structure of a protein; you need to have the right structure.
Small changes in sequence can lead to big changes in
oligomerization state, which in turn can lead to changes in
active site geometry and function (a good example can be
found in a recent study by Wei et al.:  Identification of
functional subclasses in the DJ-1 superfamily proteins.
PLoS Comput Biol 2007, 3:e10). We don’t have any method
for predicting the oligomerization state of a protein from its
sequence or its homology to a protein of known structure
when such changes occur. And what about changes in
conformation? It did Novartis no good to have the structure
of the Bcr-Abl tyrosine kinase for the design of the anti-
leukemia drug Gleevec. The kinase exists in two structural
forms, open and closed, and when Gleevec was being
developed the only existing structure was of the open form.
Gleevec binds to the closed state.
As for the stated goal of the PSI to develop technology to
make protein crystal structure determinations easier, I’m
afraid I have to say, so what? Solving structures isn’t really
the rate-determining step for most good structural biology
projects - the bottlenecks are usually biochemical. The PSI’s
focus on high-throughput methods of expression, purifica-
tion and crystallization means that it isn’t really furnishing
solutions for most of those problems. To be perfectly selfish,
I have to say that it hasn’t made any contribution to my own
work, and I’d be willing to bet that it hasn’t contributed
much to yours either.
Another problem I have is with the entire mindset of such an
initiative. It is focused on cranking stuff out as fast as
possible, with little attention to whether the structures that
it’s determining are worth determining. I also reject
categorically the notion that all protein structures are worth
having. Structures have value when they are part of a larger
effort to understand the biochemical and biological
functions of the protein in question. Doing them in isolation
has no more intellectual content than does assembling a car.
As a structural biologist, I want to train people who use
structure determination as part of what they do. It is not the
end in itself, nor should it be, not any more. When we knew
almost nothing about the universe of protein structures,
every structure had value. But Adam Smith’s law of supply
and demand works in science just as it does in economics:
with the supply of structures already in the tens of
thousands, the value of any new structure in and of itself is
likely to be rather small.
The argument can probably be made - almost certainly will
be made - that it will be useful for pharmaceutical and bio-
technology companies to have structures of all proteins
from various pathogens and from certain human disease
tissues. Maybe, though I doubt it - there’s a big difference
between a potential target and a validated one. And if such
structural information is of value to the private sector, why
shouldn’t the private sector fund it? $300 million over five
years is petty cash for a consortium of drug companies, but
I don’t see them lining up to pay even that pittance for this
information.
But what’s a drop in the bucket to drug companies is life and
death to academic research. The $60 million a year in public
money that is being spent - I would say, wasted - on the PSI
is enough to fund approximately 100-200 individual
investigator-initiated research grants. These hypothesis-
driven proposals are the lifeblood of the scientific enterprise,
and as I have discussed recently in other columns, they are
being sucked dry by, among other things, an increasing
trend to fund large initiatives at their expense. That $60
million a year would raise the payline at a typical NIH
institute by about 6 percentile points, enough to make a
huge difference to peer review and to the continuance of a lot
of important science.
I simply can’t see the justification, in a time when budgets
are so tight, for continuing a program that has produced
little useful information, has not furnished many widely
disseminated technologies or methods, and has minimal
intellectual content. Regular readers of this column (all five
of you) will know that I am not a disparager of big science
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part because their information drives good small science.
But I don’t believe that the PSI has, or that it will.
So my overall assessment of the PSI is that it is an idea whose
time has gone. Given its ability to change its shape (that is,
reformulate its goals) so as to continue to suck blood - I mean
funding - from the NIH, I think it isn’t going to be enough to
recommend that it be phased out. It should have a stake
driven through its heart, and then it should be buried in a
coffin filled with its native soil so that it can’t rise again with
the next full moon. If that seems harsh, then on its
tombstone, if you like, we could engrave the words of my
erstwhile roommate: “It seemed like a good idea at the time.”
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